Leerink raises target for Twist Bioscience stock from USD 120 to USD 160

Published on 10/05/2026 at 06:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 118.38 million in fiscal third quarter 2026, up 23.20 percent. Twist Bioscience stock had a EUR 167.68 prior close on October 2, 2026.

TWST, US90184D1000, Illustration mit AI erstellt.

Leerink Partners raised its Twist Bioscience stock target from USD 120.00 to USD 160.00 and reiterated an Outperform rating in a note dated September 17, 2026, as MarketBeat reported. The move gives investors a concrete measure of how the analyst view changed as Twist expanded its synthetic biology and drug-discovery activity.

Revenue grew, losses persisted

Twist reported USD 118.38 million of revenue in fiscal third quarter 2026, a 23.20 percent increase from the same quarter a year earlier, according to MarketBeat. The quarter also produced a USD 0.56 loss per diluted share, compared with a USD 0.51 consensus loss, a USD 0.05 miss that keeps profitability central to the stock story.

The finance statement for the same period showed gross profit of USD 62.45 million and a 53.00 percent gross margin. Net loss was USD 35.05 million, while operating cash flow was USD 1.12 million, making revenue growth the clearest positive operating comparison and earnings quality the main counterweight.

Targets diverge from market value

Leerink's USD 160.00 target sits below the Nasdaq last price of USD 188.67 on October 2, 2026 at 4:00 p.m. ET. The same market quote put Twist's market capitalization at USD 11.7 billion and its 52-week range at USD 23.30 to USD 200.31 on that date.

MarketBeat reported eight Buy ratings, two Hold ratings and two Sell ratings, with a USD 103.00 average target. That spread shows the debate clearly: analysts recognize 23.20 percent revenue growth, while the valuation already reflects expectations well beyond the latest loss-making quarter.

Prior close anchors the euro view

The Lang & Schwarz prior close was EUR 167.68 on October 2, 2026. Twist Bioscience Corporation develops synthetic DNA, next-generation sequencing tools and antibody libraries through a silicon-based manufacturing platform.